Work

Δ8‐Tetrahydrocannabivarin has potent anti‐nicotine effects in several rodent models of nicotine dependence

Year: 2019

Type: article

Abstract: Background and Purpose Both types of cannabinoid receptors—CB1 and CB2—regulate brain functions relating to addictive drug‐induced reward and relapse. CB1 receptor antagonists and CB2 receptor agonists have anti‐addiction efficacy, in animal models, against a broad range of addictive drugs. Δ9‐Tetrahydrocannabivarin (Δ9‐THCV)—a cannabis constituent—acts as a CB1 antagonist and a CB2 agonist. Δ8‐Tetrahydrocannabivarin (Δ8‐THCV) is a Δ9‐THCV analogue with similar combined CB1 antagonist/CB2 agonist properties. Experimental Approach We tested Δ8‐THCV in seven different rodent models relevant to nicotine dependence—nicotine self‐administration, cue‐triggered nicotine‐seeking behaviour following forced abstinence, nicotine‐triggered reinstatement of nicotine‐seeking behaviour, acquisition of nicotine‐induced conditioned place preference, anxiety‐like behaviour induced by nicotine withdrawal, somatic withdrawal signs induced by nicotine withdrawal, and hyperalgesia induced by nicotine withdrawal. Key Results Δ8‐THCV significantly attenuated intravenous nicotine self‐administration and both cue‐induced and nicotine‐induced relapse to nicotine‐seeking behaviour in rats. Δ8‐THCV also significantly attenuated nicotine‐induced conditioned place preference and nicotine withdrawal in mice. Conclusions and Implications We conclude that Δ8‐THCV may have therapeutic potential for the treatment of nicotine dependence. We also suggest that tetrahydrocannabivarins should be tested for possible anti‐addiction efficacy in a broader range of preclinical animal models, against other addictive drugs, and eventually in humans.

Source: British Journal of Pharmacology

DOI: 10.1111/bph.14844